Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01558323 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 2
- Study locations
NCT01558323: Completed Phase 1 study of Renal Impairment, sponsored by Novartis Pharmaceuticals.
NCT01558323 is a Phase 1 study of Renal Impairment that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 58 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (76% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01558323, a Phase 1 study of Renal Impairment, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
Conditions Studied
Interventions
- DRUG LCQ908
Study Locations (2)
Florida
- Novartis Investigative Site - Orlando
Tennessee
- Novartis Investigative Site - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
What the finished NCT01558323 record still lists
NCT01558323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which LCQ908 is the first listed.
NCT01558323 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01558323 about?
NCT01558323 is a clinical study titled "Pharmacokinetics of LCQ908 in Patients With Renal Impairment". This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
What is the current status of trial NCT01558323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2012-05. Estimated completion is 2013-03.
What conditions does trial NCT01558323 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT01558323?
The interventions under investigation include: LCQ908 (DRUG).
Who is sponsoring clinical trial NCT01558323?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01558323 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01558323's enrollment target sits among peer trials
58 3rd of 32 higher than 29 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia